Trial Profile
A Multicenter, Randomized, Open-label, Phase II Trial Aiming to Evaluate the Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2 Positive Breast Cancer Patients
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Pegfilgrastim (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary)
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms BREASTIMMU02
- 11 Feb 2022 Planned End Date changed from 1 Apr 2022 to 1 Apr 2024.
- 11 Feb 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Apr 2024.
- 31 Aug 2021 Planned End Date changed from 1 Nov 2021 to 1 Apr 2022.